Evidence map›Paper›PMID 40140749›Full record

ArticleBMC infectious diseases2025

Machine learning-based prognostic model for bloodstream infections in hematological malignancies using Th1/Th2 cytokines.

Qin Li, Nan Lin, Zuheng Wang, Yuexi Chen, Yuli Xie, Xuemei Wang, Jirui Tang, Yuling Xu, Min Xu, Na Lu and 4 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qin Li *Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Nan Lin *Department of Internal Medicine, Longmatan District Hospital of Traditional Chinese Medicine, Luzhou, Sichuan, 646000, China.
Zuheng WangDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Yuexi ChenThe Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, Luzhou, Sichuan, 646000, China.
Yuli XieDepartment of lmmunology, School of Basic Medical Sciences, Guangxi Medical University, Nanning, Guangxi, 530021, China.
Xuemei WangDepartment of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Jirui TangDepartment of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
Yuling XuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Min XuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Na LuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Yiqian HuangDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Jiamin LuoDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Zhenfang LiuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. liuzhenfang@gxmu.edu.cn.
Li JingDepartment of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China. 2251270990@qq.com.

Funding

National Natural Science Foundation of China No. 82160039Research Foundation of Southwest Medical University 2024ZKY027
6 · The paper itself

Abstract

objectiveBloodstream infection (BSI) is a significant cause of mortality in patients with hematologic malignancies(HMs), particularly amid rising antibiotic resistance. This study aimed to analyze pathogen distribution, drug-resistance patterns and develop a novel predictive model for 30-day mortality in HM patients with BSIs.

methodsA retrospective analysis of 231 HM patients with positive blood cultures was conducted. Logistic regression identified risk factors for 30-day mortality. Th1/Th2 cytokines were collected at BSI onset, with LASSO regression and restricted cubic spline analysis used to refine predictors. Seven machine learning(ML) algorithm (XGBoost, Logistic Regression, LightGBM, RandomForest, AdaBoost, GBDT and GNB) were trained using 10-fold cross-validation and model performance was evaluated with the ROC, calibration plots, decision and learning curves and the Shapley Additive Explanations (SHAP) analysis. The predictive model was developed by integrating Th1/Th2 cytokines with clinical features, aiming to enhance the accuracy of 30-day mortality prediction.

resultsAmong the cohort, acute myeloid leukemia (38%) was the most common HM, while gram negative bacteria (64%) were the predominant pathogens causing BSI. Age, polymicrobial BSI, IL-4, IL-6 and AST levels were significant predictors of 30-day mortality. The Logistic Regression model achieved AUCs of 0.802, 0.792, and 0.822 in training, validation, and test cohorts, respectively, with strong calibration and clinical benefit shown in decision curves. SHAP analysis highlighted IL-4 and IL-6 as key predictors.

conclusionsThis study introduces a novel ML-based model integrating Th1/Th2 cytokines and clinical features to predict 30-day mortality in HM patients with BSIs, demonstrating strong performance and clinical applicability.

Indexed as

BacteremiaCytokinesHematologic NeoplasmsMachine LearningSepsisTh1 CellsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsTh2 CellsCytokinesBloodstream infectionHematological malignancyMachine learningMicrobiologyModelResistanceRisk factor

Identifiers

PMID40140749
PMCPMC11948653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.